Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
Recruiting
Observational Study
Coronary Artery Disease
Acute Kidney Injury
Contrast-Induced Acute Kidney Injury
Percutaneous Coronary Intervention
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 4,000 (estimated)
- Sponsor
- Collegium Medicum w Bydgoszczy · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion.
The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available.
The primary objective of t…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* all consecutive patients who underwent PCI or coronary angiography during the study period for whom the variables required for the analysis are available
Exclusion Criteria:
* unavailability of variables required for the analysis, volume
* contrast agent volume \<50 mL or \>…
Contacts